Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:CASNumber |
142732-53-6
|
| gptkbp:chemicalFormula |
C10H15N
|
| gptkbp:derivedFrom |
amphetamine
|
| gptkbp:describedBy |
gptkb:PiHKAL
|
| gptkbp:discoveredBy |
gptkb:Alexander_Shulgin
|
| gptkbp:effect |
stimulant
|
| gptkbp:hasAziridineRing |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
ADDP
|
| gptkbp:IUPACName |
1-phenyl-2-propan-2-ylaziridine
|
| gptkbp:legalStatus |
uncontrolled (most countries)
|
| gptkbp:molecularWeight |
149.23 g/mol
|
| gptkbp:otherName |
2,3-dihydro-1H-azirine, 1-phenyl-2-(propan-2-yl)-
|
| gptkbp:psychoactive |
yes
|
| gptkbp:relatedTo |
amphetamine
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:bfsParent |
gptkb:Association_of_Developmental_Disabilities_Providers
|
| gptkbp:bfsLayer |
8
|